Darbepoetin Alfa (Aranesp) Global Market Research Report 2023 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Darbepoetin Alfa (Aranesp) Global Market Report 2023” report has been added to ResearchAndMarkets.com’s offering.

The global darbepoetin alfa (Aranesp) market is expected to grow from $5.25 billion in 2022 to $5.56 billion in 2023 at a compound annual growth rate (CAGR) of 6%. The darbepoetin alfa (Aranesp) market is expected to reach $6.73 billion in 2027 at a CAGR of 4.9%.

Darbepoetin alfa (Aranesp) is a medication used to treat anemia brought on by chemotherapy and chronic kidney disease. It helps the bone marrow make more red blood cells.

Darbepoetin alfa, which includes products like Epogen, Procrit, Aranesp, and others, plays a vital role in the treatment of anemia, particularly in the context of chronic diseases. Anemia is characterized by a shortage of red blood cells in the body, and darbepoetin alfa serves to stimulate the production of these cells.

The prevalence of chronic diseases is on the rise, and this trend is expected to drive the growth of the darbepoetin alfa market. Chronic diseases are long-term illnesses that can worsen over time and persist for three months or more. Darbepoetin alfa is employed in the treatment of various chronic diseases, including chemotherapy-induced anemia in cancer patients.

For example, according to the National Library of Medicine in January 2023, the number of individuals aged 50 and older in the United States with at least one chronic condition is projected to surge by 99.5%, from 71.522 million in 2020 to 142.66 million by 2050. This substantial increase in the prevalence of chronic diseases is a significant driver of the darbepoetin alfa market.

The darbepoetin alfa market encompasses the sale of products like Aranesp SureClick, Aranesp Albumin Free, and Aranesp Singleject. The values presented in this market are “factory gate” values, representing the worth of goods sold by the creators or manufacturers, either to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end consumers. These values also encompass any related services offered by the goods’ creators.

Product innovation is a prominent trend in the darbepoetin alfa market, with major companies adopting new technologies to maintain their market positions. For instance, in February 2023, GlaxoSmithKline Ltd., a UK-based pharmaceutical and biotechnology company, secured approval from the US Food and Drug Administration (FDA) for Jesduvroq (daprodustat). Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, which is a once-daily treatment for anemia resulting from chronic kidney disease in individuals on dialysis for at least four months.

In 2022, North America emerged as the largest region in the darbepoetin alfa market. The regions covered in the darbepoetin alfa report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, and the Middle East and Africa. The countries analyzed in the report encompass Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, the USA, Canada, Italy, and Spain.

Major players in the darbepoetin alfa (Aranesp) market are

• Johnson & Johnson
• Amgen Inc.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Serum Institute of India Pvt. Ltd.
• Dr. Reddy’s Laboratories Ltd.
• Cipla Ltd.
• Biocon Ltd.
• Reliance Life Sciences
• Torrent Pharmaceuticals Ltd.
• 3SBio Inc.
• Cadila Healthcare Ltd.
• Dong-A ST Co. Ltd.
• Chong Kun Dang Holdings
• Hetero Drugs Ltd.
• Intas Pharmaceuticals Ltd.
• Avesthagen Pharma
• Stada Arzneimittel AG
• Ranbaxy Laboratories Ltd.
• Sandoz International GmbH
• Shandong Kexing Bioproducts Co. Ltd.
• Iko Pharmaceutical Co. Ltd.
• Menagen Pharmaceutical Industries
• Kyowa Kirin Co. Ltd.
• Polifarma S.p.A.

Key Topics Covered:

1. Executive Summary

2. Darbepoetin Alfa (Aranesp) Market Characteristics

3. Darbepoetin Alfa (Aranesp) Market Trends And Strategies

4. Darbepoetin Alfa (Aranesp) Market – Macro Economic Scenario

4.1. Impact Of High Inflation On Online Therapy Services Market

4.2. Ukraine-Russia War Impact On Online Therapy Services Market

4.3. COVID-19 Impact On Online Therapy Services Market

5.1. Global Darbepoetin Alfa (Aranesp) Historic Market Size and Growth, 2017 – 2022, Value ($ Billion)

5.2. Global Darbepoetin Alfa (Aranesp) Forecast Market Size and Growth, 2022 – 2027, 2032F, Value ($ Billion)

5.3. Global Darbepoetin Alfa (Aranesp) Market Drivers and Restraints

5.3.1. Drivers Of The Market

5.3.2. Restraints Of The Market

6. Darbepoetin Alfa (Aranesp) Market Segmentation

6.1. Global Darbepoetin Alfa (Aranesp) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

• Epogen
• Procrit
• Aranesp
• Other Types

6.2. Global Darbepoetin Alfa (Aranesp) Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

6.3. Global Darbepoetin Alfa (Aranesp) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

• Patients with Chronic Kidney Disease
• Patients with Cancer
• Other Applications

7. Darbepoetin Alfa (Aranesp) Market Regional And Country Analysis

7.1. Global Darbepoetin Alfa (Aranesp) Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

7.2. Global Darbepoetin Alfa (Aranesp) Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

For more information about this report visit https://www.researchandmarkets.com/r/aenzav

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900